M2I Life Sciences strengthens its CSR to attract funds and talents
NEW YORK and MAINZ, Germany, October 4, 2021—Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ COVID-19 vaccine as a booster dose at least six months after the second dose in individuals 18?years of age and older. The European Commission (EC) will review the CHMP recommendation and is expected to make a final decision on a variation to the Conditional Marketing Authorization in the near future. If the EC grants the variation regarding a booster dose, the decision will be immediately applicable to all 27 EU member states.
Turning to the sustainable and the biological, Agri Star started the touch load more than ten years ago. AgroPages reports the cooperation between Certis US, CEV S.A. and Agri Star, as the company continues to bring and commercialize biological products to the Argentina market. As Eng. Ezequiel Nardini, said, “It is the right way to go and Agri Star has contributed in satisfying the organic and low-residue market demand.”
Finding the green path forward
M2i among the list of the deeptech startups in agriculture of the Public Investment Bank France which are transforming the
The government has appointed M2i among the 31 winners of its industrial recovery plan thanks to our project to produce GAMMA-OH molecules within our production site in Salin-de-Giraud (13). This molecule has been widely used this year in the management of intensive care patients suffering from Covid-19.
If one were to sum up in a few words the unusual career of Philippe Guerret up to the creation of M2i Life Sciences in 2012, it would be a story of experimentation and a rapid rise to positions of responsibility: creation of PepsiCo in France, management of audiovisual rights with UGC as it was being bought out by Canal+ (with, in his own words, “absolutely astounding tax dossiers for a young graduate”), Vinci’s IPO and the launch of its airport contracts, all before he had even turned 30. Already in the deep end, Philippe Guerret was oscillating between Miami and Switzerland, excelling when it came to repositioning firms in difficulty and specialising in duty-free. Always one step ahead, he had an eye on the future and his next potential business sector, until he was thunderstruck by the world of industry.
Our plant has been launched a production of 10 tonnes of hydroalcoholic gel to support French hospitals around the plant.
M2i Life Sciences raises 60 mln euros
Directeur général de M2i Life Sciences, depuis 2019, après plus de 20 ans de carrière chez PCAS puis Seqens, Vincent Touraille prend la direction de la stratégie et des M&A (merger & acquisitions) au sein de l’activité chimie de Sanofi, baptisée Sanofi Active Ingredient Solutions (SAIS). Dotée de quinze sites de production pharma et biotech et employant plus de 2000 collaborateurs, cette activité devrait donner naissance en 2022 à un nouveau numéro deux mondial de la chimie fine pharmaceutique, derrière Lonza. Six usines ont été retenues pour faire partie de l'aventure : les deux françaises, Saint Aubin-lès-Elbeuf et Vertolaye, ainsi que les sites de Brindisi (Italie), Francfort Chimie (Allemagne), Haverhill (Royaume-Uni) et Újpest (Hongrie).